Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of BLU-263 in Healthy Volunteers

Trial Profile

A Phase I Trial of BLU-263 in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elenestinib (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Blueprint Medicines

Most Recent Events

  • 17 Jun 2021 Results assessing safety, tolerability, and pharmacokinetics of BLU-263 in normal healthy volunteers, presented at the 26th Congress of the European Haematology Association.
  • 11 Apr 2021 According to a Blueprint Medicines media release, data from this study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
  • 11 Apr 2021 Results published in the Blueprint Medicines media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top